Q-omics provides the consensus-scored EVX2 profile across patient tissues and cancer cell-line models. EVX2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, EVX2 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, EVX2 RNA expression shows 12,858 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KIRP, and TGCT as cancer lineages where EVX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EVX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EVX2 survival associations across molecular data types. EVX2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EVX2 RNA expression–survival associations across cancer types. High EVX2 expression shows unfavorable associations in COAD, ACC, LGG, CHOL, STAD and BLCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for EVX2 RNA expression.
This table summarizes EVX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for EVX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EVX2 shows lower tumor expression in COAD, READ and PRAD and higher tumor expression in KIRP, LUSC and HNSC. The KIRP box plot shows higher EVX2 RNA expression in tumor versus normal tissue (log2 FC = +0.100, t-test p = .004).
This table shows molecular features associated with EVX2 in patient tissues and cancer cell lines. In patient samples, EVX2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, EVX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
